Live Chat ×
Skip to main content

Ask the Experts Webinar: Update on the Evidence for Treatment of Infantile Spasms

Activity provided by the American Epilepsy Society.
Recording date: July 24, 2018
Release date: July 26, 2018
Expiration date(nursing credits): July 26, 2020
Expiration date (physician and participation credits): July 26, 2021

To View the Enduring Activity, Click Here

Overview

Infantile spasms represent an age related epileptic encephalopathy. Outcomes depend on several modifiable risk factors such as early recognition of the syndrome, appropriate treatment, and appropriate follow up, also on etiology which is usually not modifiable. This webinar will provide an update on the evidence for treatment of infantile spasms with a focus on short term outcomes, the challenge of relapse after initiation of treatment and how other factors such as etiology impact treatment choice and outcomes.

References
Knupp KG, Coryell J, Nickels KC, et al. Response to treatment in a prospective national infantile spasms cohort. Ann Neurol 2016; 79:475-484.
Mytinger JR, Joshi S. The current evaluation and treatment of infantile spasms among members of the child neurology society. J Child Neurol 2012; 27:1289-1294.
Wheless JW, Clarke DF, Carpenter D. Treatment of pediatric epilepsy: expert opinion, 2005. J Child Neurol 2005;20 Suppl 1: S1-56; quiz S59-60.
Knupp KG, Leister E, Coryell J, et al. Response to second treatment after initial failed treatment in a multicenter prospective infantile spasms cohort. Epilepsia 2016; 57:1834-1842.

Target Audience
Epileptologists, neurologists, pharmacologists, advanced practice providers, nurses and epilepsy specialist allied health professionals

Learning Objectives
Following participation in this activity the learner should be able to:

  • review current evidence on short-term benefits and risks of Infantile Spasms (IS) treatment
  • review the challenge of IS relapse
  • discuss how etiology impacts treatment choice and outcome

Faculty

Moderator:
Dennis J. Dlugos, MD, Children's Hospital of Philadelphia, Philadelphia, PA
Chair, AES Education and Professional Development Committee

Presenter: 
Kelly Knupp, MD, Children's Hospital Colorado, Aurora, CO


Disclosure Policy

It is the policy of the American Epilepsy Society to ensure balance, independence, objectivity and scientific rigor. All individuals involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. Conflicts of interest will be resolved by AES prior to an educational activity being delivered to learners. 


Faculty, Planning Committee, Reviewers’ Disclosures of Financial Relationship

In accordance with the ACCME Standards for Commercial Support, the AES requires that any person who is in a position to control content of a CME activity must disclose all relevant financial relationships that they have with a commercial interest. The following individuals contributed to this activity’s content.

Faculty & Planners
Dennis Dlugos, MD, Children's Hospital of Philadelphia, Philadelphia, PA
Dr. Dlugos has disclosed the following relationships:
  • Salary support from the Commonwealth of Pennsylvania Department of Health,  from NIH-NINDS, and The Epilepsy Study Consortium for research activities.
Kelly Knupp, MD, Children's Hospital Colorado, Aurora, CO
Dr. Knupp has disclosed the following relationships:
  • Zogenix: Contracted research; Greenwich Pharmaceuticals (DSMB): consulting fee; Colorado Department of Public Health and Environment: research funding; West Therapeutics: contracted research; Pediatric Epilepsy Foundation: research funding.
Nurse Planner
Madona Plueger, MSN, RN, APRN, ACNS-BC, Barrow Neurological Institute, Phoenix, AZ
Ms. Plueger has indicated she has no financial relationships with commercial interests to disclose.

CME Reviewer
Ignacio Valencia, MD, St. Christopher's Hospital for Children, Philadelphia, PA
Dr. Valencia has indicated he has no financial relationships with commercial interests to disclose.

American Epilepsy Society Staff Planner
Amy Kephart, MPH
Ms. Kephart has indicated she has no financial relationships with commercial interests to disclose. 

ACCME-defined Commercial Interest: Any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on, patients.

Resolution of Conflicts of Interest

It is the policy of the American Epilepsy Society to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. In accordance with the ACCME Standards for Commercial Support of CME, the AES implemented the mechanisms of prospective peer review of this CME activity, to identify and resolve any conflicts. Additionally, the content of this activity is based on the best available evidence.

Accreditation 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The American Epilepsy Society is accredited by the ACCME to provide continuing medical education for physicians.

This activity has been submitted to Montana Nurses Association for approval to award contact hours. Montana Nurses Association is accredited as an approver of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. 

Credit Designation

The American Epilepsy Society designates this enduring material internet activity for a maximum of .5 AMA PRA Category 1 Credit™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

International Credits: The American Medical Association has determined that non-US. licensed physicians who participate in this CME activity are eligible for AMA PRA Category 1 Credits™.

Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.5 hours of Category 1 credit for completing this program.

Nurses: This continuing nursing education activity was approved by the Montana Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. This activity has been approved for 0.5 contact hours of continuing nursing education.

CME and CE Certificates
To receive credit for your participation in this activity, please complete the evaluation survey provided at the conclusion of the activity.

Unapproved Use Disclosure

The American Epilepsy Society requires CME authors to disclose to learners when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information. Information about pharmaceutical agents/devices that is outside of U.S. Food and Drug Administration approved labeling may be contained in this activity.

Disclaimer


This CME activity is for educational purposes only and does not constitute the opinion or endorsement of, or promotion by, the American Epilepsy Society. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label, investigational and/or experimental uses.